Clinical Trials Logo

Clinical Trial Summary

Obsessive Compulsive Disorder (OCD) is a condition associated with recurrent intrusive distressing thoughts, images and urges compelling the person to perform neutralizing acts or thoughts to the extent of significantly interfering with their daily activities. The symptoms of OCD are associated with both subjective and objective signs of distress. Treatment for Obsessive Compulsive Disorder is often associated with significant subjective distress with high dropout rates and often only limited improvement. Attempts to reduce distress in anxiety often focus on re-establishing the sympathovagal balance by enhancing the vagal or parasympathetic tone and it has been suggested that this can reduce the mobilization behaviours of fight or flight response and improve emotion regulation. This study will investigate the effect of a procedure potentially reducing distress and improving outcome of treatment in inpatients admitted for treatment for OCD to the Anxiety Disorders Residential Unit. The procedure will be based on increasing vagal tone by application of cold face mask on 3 consecutive days in addition to the standard Exposure and Response Prevention therapy (ERP).


Clinical Trial Description

1. Background

Obsessive Compulsive Disorder (OCD) is a condition associated with recurrent intrusive distressing thoughts, images and urges compelling the person to perform neutralizing acts or thoughts to the extent of significantly interfering with their daily activities. The symptoms of OCD are associated with both subjective and objective signs of distress. Psychophysiological studies of OCD and other anxiety disorders often report abnormal sympathovagal balance with decreased parasympathetic or vagal tone and increased sympathetic tone (Hoehn-Saric et al 1995, Broderick et al 2013, Kawano et al 2012, Pittig et al 2013, Buhlmann et al 2007, Blechert et al 2007, Friedman and Thayer 1998).

The first line treatment of OCD is Cognitive Behaviour Therapy (CBT) which includes Exposure and Response Prevention (ERP) when the patient tests out their fears without responding by compulsive act (NICE Clinical Guideline 31). ERP treatment itself is often associated with significant subjective distress (Kellner et al 2012) with dropout rates up to 20% and only minimal improvement in another 20% of patients (Foa 2010). Various modalities of treatment reducing the subjective and physiological distress have been used in treatment of anxiety disorders and symptoms (Streeter et al 2012, Miu et al 2009, Gorman et al 2000) and similar approach could increase the rates of improvement and adherence to ERP treatment in OCD. Most of the attempts to reduce distress in anxiety focus on re-establishing the sympathovagal balance by enhancing the vagal or parasympathetic tone and it has been suggested that this can reduce the mobilization behaviours of fight or flight response and improve emotion regulation (Austin et al 2007). Disgust is an emotion implicated to have significant role on anxiety disorders such as OCD with contamination fears (Moretz and McKay 2008). It has been shown to have only limited response to exposure therapy (Olatunji et al 2009) and can be associated with increased avoidance and reduced compliance with exposures (Olatunji et al 2007) possibly contributing to poorer treatment outcome. Disgust can be associated with changes in sympathovagal balance (Ottaviani et al 2013) but the effect of manoeuvres affecting this balance has not been tested.

Vagal tonus can be increased with specific procedures called vagal manoeuvres. These include the diving reflex, Valsalva manoeuvre, pressure on the eyeball and carotid sinus massage, with the diving reflex being one of the most effective (Arnold 1999). The diving reflex is a phylogenetically ancient physiological phenomenon believed to facilitate survival after immersion in cold water through bradycardia and peripheral vasoconstriction redistributing blood flow to vital organs (Gooden 1994). The combined bradycardia and vasoconstriction effect indicates on complex sympathovagal activation and the bradycardia itself is believed to be due to central vagal activation (Stemper et al 2002). The natural trigger for diving reflex includes change in body position, apnoea and sensation of cold and wet surface on the face and a cold sensation on the face is sufficient to induce the vagal response. This is believed to be transmitted by the ophthalmic branch of the trigeminal nerve and can be achieved by using cold compressions or cold face gel masks (Khurana et al. 1980).

The physiological response during diving reflex can be measured by recording standard physiological measures such as heart rate, blood pressure or skin conductance. Heart rate and its interpretation in terms of heart rate variability is becoming more frequently utilized to evaluate the balance between sympathetic and parasympathetic nervous system. Most frequently used is the frequency domain approach which allows differentiating specific frequency bands. The low frequency (LF) band groups the variability between 0.05-0.15Hz and is believed to represent the sympathetic cardiac control with slower unmyelinated nerve fibres while the high frequency (HF) band including frequencies between 0.15-0.4Hz reflects the parasympathetic or vagal control with faster myelinated nerve fibres (Berntson et al 1997).

2. Aims of the study

The aim of the study is to evaluate the effect of a simple vagal manoeuvre, that is a cold face gel mask application, on subjective measures of Anxiety, Disgust, Strength of belief in obsession, Strength of urge to carry out the compulsion, Strength of belief in Theory A/B and an increase in Feeling of being supported, Readiness to face the fear during the ERP treatment of OCD by using a single-case series experimental design and to explore the relationship between subjective measures and sympathovagal balance measured by heart rate variability. Our hypothesis is that:

1. ERP with application of cold gel face mask (Condition B) will be associated with faster reduction of visual analogue scales of Anxiety, Disgust, Strength of belief in obsession, Strength of urge to carry out the compulsion, Strength of belief in Theory A/B and an increase in Feeling of being supported, Readiness to face the fear compared to ERP as usual with simply resisting the compulsive behaviour (Condition C).

2. Increase in vagal tonus as documented by heart rate variability measures will correlate with the effect on visual analogue scales of Anxiety, Disgust, Strength of belief in obsession, Strength of urge to carry out the compulsion, Strength of belief in Theory A/B, Feeling of being supported and Readiness to face the fear.

3. Methods

i. Participants: Participants will be recruited from the Anxiety Disorders Residential Unit (ADRU), Bethlem Royal Hospital. All patients admitted to ADRU have the opportunity to consent to be contacted about participating in research studies. Only patients admitted to ADRU for treatment of OCD who provided such initial consent will be approached by Dr Roman Duncko regarding the written informed consent to participate in the present study.

ii. Procedure and Design: On each day of the study, therapy will begin with the Baseline phase (Condition A) and record the psychological (visual analogue scales of Anxiety, Disgust, Belief in obsession, Strength of urge for compulsion, Strength of belief in Theory A/B, Feeling of being supported, Readiness to face the fear) and physiological measures (HR recording) on 3-5 consecutive 5min intervals or until stable baseline measures are achieved. After that, the participant will proceed with the Intervention phase by applying ERP with the use of triggers as identified on their individual hierarchy. Each ERP session will follow the same structure by first obtaining the session baseline at 3 time points, then exposure to trigger and continue with preventing the response while applying the cold face mask for 5 minutes (Condition B) or without using the face mask (Condition C). Psychological and physiological measures will be obtained in 5 minute intervals until return to session baseline. ERP sessions will follow in alternating order for 4 sessions per day (Day 1: ABCBC, Day 2: ACBCB, Day 3: ABCBC). All baseline and exposure measures will be recorded by the investigator who will by accompanying the participant during the procedure. Cold face gel masks will be stored in refrigerator at the ADRU and will be available to the participant as required.

iii. Psychological measures: Visual analogue scales for measurement of severity of Anxiety, Disgust, Strength of belief in obsession, Strength of urge to carry out the compulsion, Strength of belief in theory A/B, Strength of belief in Theory A/B, Feeling of being supported, Readiness to face the fear will be used by the participant at time points as specified above. In addition to this the participant will be assessed for their clinical symptoms (YBOCS, OCI) on weekly basis as part of their standard treatment plan.

On the last day of the study, participants will be asked to complete the Client Satisfaction Questionnaire based on (Larsen et al 1979) to explore the feasibility and acceptability of the cold face gel mask application during ERP.

iv. Physiological measures: Heart rate variability analysis will be performed on data recorded with a Polar RS800CX heart rate monitor using a H2 chest sensor. Polar monitors have been tested against standard clinical ECG equipment and found to be suitable for heart rate variability analysis (Vanderlei et al 2008). In the morning of the study day, the participants will place the Polar heart rate sensor on their chest using the elastic strap. They will be instructed how to use the heart rate monitor watch Polar RS800CX to record the heart rate and press the mark recording button at specific times during each procedure. At the end of each study day, the data will be downloaded from the heart rate monitor watch and 3 time intervals of 2 minutes will be identified: at the beginning of the condition - time 0, at the beginning of the procedure - time 15, at the end of the condition - time 45. Time intervals will be screened for artefacts and used for heart rate variability analysis using standalone analysis software (Niskanen et al 2004). Variables selected for analysis will include heart rate per minute, time domain measures (RMSSD, NN50) and frequency domain measures (nLF at 0.05-0.15Hz, nHF at 0.15-0.04Hz, LF/HF).

v. Data analysis: Data will be initially evaluated by visual inspection for each participant individually. After that, values obtained for a specific time interval and phase will be averaged among all participants and again evaluated by visual inspection. Percentage of non-overlapping data analysis will be performed to detect statistically significant change between the baseline and intervention phase. Pearson's correlation will be used for correlation analyses.

4. Project timetable

The project is planned to run for 6-12 months depending on the rate of recruitment of participants.

5. Expertise in team

Dr David Veale is a consultant psychiatrist in Cognitive Behaviour Therapy at the South London and Maudsley Trust and a Honorary Senior Lecturer at the Institute of Psychiatry, Kings College London. Specialisms include obsessive compulsive disorder.

Dr Roman Duncko, PhD is a ST5 trainee in General Adult Psychiatry at the South London and Maudsley Trust with long-term research interest in anxiety disorders and autonomic nervous system function.

6. Ethical considerations

All ethical considerations are outlined in the Participant Information and Consent Form that will be distributed to participants. All patients admitted to ARDU who fulfil the inclusion criteria will be approached about participating in the study. All participants will require signing an informed consent to participate. All information and data obtained during the study will be kept in strict confidence. Upon recruitment, every participant will be assigned an anonymous code and the lists linking the code with personal identifying information will be kept secure and separate from the data. Only the Principal Investigator and researchers authorized by the PI will have access to the identifying lists. Every participant will undergo the same procedures with slightly variable order. No deception will be used and participants will be informed as to exactly what the study is about. All participants will be informed at the time of providing consent to participate that they can withdraw from the study at any time and that this will not affect the care they will receive.

7. Dissemination and implementation

Results of the study will be used for poster and/or oral presentations at suitable conferences and for preparing a manuscript for submission in a scientific journal. Depending on the outcome of the study further research will be planned to evaluate the effect of cold face gel mask in a study with randomized control trial design. ;


Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT02196090
Study type Interventional
Source King's College London
Contact Roman Duncko, PhD MRCPsych
Phone +44(0)2032284545
Email roman.duncko@slam.nhs.uk
Status Recruiting
Phase N/A
Start date July 2014
Completion date February 2016

See also
  Status Clinical Trial Phase
Recruiting NCT04631042 - Developing Brain, Impulsivity and Compulsivity
Completed NCT02855580 - Integrating Pharmacogenomic Testing Into a Child Psychiatry Clinic
Completed NCT02229903 - An Evaluation of the Safety and Efficacy of the dTMS Treatment for OCD N/A
Completed NCT02202915 - CBT for Pediatric OCD: Community Training Pilot N/A
Completed NCT01794156 - Evaluation of a Cognitive Therapy (Inference-based-therapy) for the Treatment of Obsessional Compulsive Disorder N/A
Completed NCT02089984 - Web Based Therapist Training on Cognitive Behavior Therapy for Anxiety Disorders N/A
Completed NCT01348529 - Internet Cognitive Behavior Therapy (CBT) for Obsessive Compulsive Disorder (OCD) N/A
Recruiting NCT00965211 - Evaluation of the HBDL Coil Transcranial Magnetic Stimulation (TMS) Device - Safety and Feasibility Study for the Treatment of Tourette Syndrome N/A
Completed NCT00723060 - Comparison of Effects Between Conventional Dose and High Dose Escitalopram on Clinical Improvement in Patients With Obsessive-compulsive Disorder Phase 4
Completed NCT01172873 - D-Cycloserine Augmentation to CBT With Exposure and Response Prevention in Adults and Adolescents With OCD N/A
Not yet recruiting NCT00743834 - Cost-Effectiveness of Adding Web-Based Cognitive-Behavioral Therapy (CBT) to Luvox CR for Obsessive Compulsive Disorder (OCD) Phase 4
Completed NCT02421315 - Overlapping Neural Circuits in Pediatric OCD N/A
Completed NCT02194075 - Methylphenidate Hydrochloride Controlled-Release Tablets Augmentation Strategy for Patients With Obsessive Compulsive Disorder Phase 4
Completed NCT01981317 - Stepped Care Cognitive Behavioral Therapy for Pediatric Obsessive Compulsive Disorder N/A
Completed NCT01686087 - Attaining and Maintaining Wellness in Obsessive-compulsive Disorder N/A
Terminated NCT00997087 - A Randomized, Double-Blind, Placebo-Controlled Trial of Flumazenil for the Treatment of Obsessive Compulsive Disorder Phase 2
Completed NCT01331876 - Modification of Cerebral Activity of Obsessive Compulsive Disorder (OCD) Patients During Cognitive and Behavioral Therapy N/A
Completed NCT00533806 - Comparing the Effectiveness of Two Family-based Therapies in Treating Young Children With Obsessive-Compulsive Disorder Phase 3
Completed NCT00517244 - Evaluating Parenting Styles and Child Temperament Associated With Child Anxiety Disorders N/A
Completed NCT00169377 - Subthalamic Nucleus (STN) Stimulation and Obsessive-Compulsive Disorder (OCD) Phase 1/Phase 2